

1 **Peripheral artery disease affects the legs of claudicating patients in a diffuse manner**
2 **irrespective of the level of the arterial tree primarily involved.**

3 Article Type: Original Paper

4 Todd J. Leutzinger, MS¹, Panagiotis Koutakis, PhD², Matthew A. Fuglestad, MD³, Hafizur
5 Rahman, PhD, Holly Despiegelaere RN⁴, Mahdi Hassan, MS, Molly Schieber, MS, Jason M.
6 Johanning, MD^{3,4}, Nick Stergiou, PhD^{1,5}, G. Matthew Longo, MD³, George P. Casale³, Sara A.
7 Myers, PhD^{1,3**}, Iraklis I. Pipinos, MD^{1,3,4**}

8 ¹Department of Biomechanics and Center for Research in Human Movement Variability,
9 University of Nebraska at Omaha, Omaha, NE

10 ²Department of Biology, Baylor University, Wako, TX

11 ³ Department of Surgery, University of Nebraska Medical Center, Omaha, NE

12 ⁴ Department of Surgery and Research Service, Nebraska and Western Iowa Veterans Affairs
13 Medical Center, Omaha, NE

14 ⁵Department of Environmental Agricultural and Occupational Health, University of Nebraska
15 Medical Center, Omaha, NE

16 **** Corresponding Authors:**

17 Sara A. Myers
18 6001 Dodge St, BRB 212
19 Omaha, NE 68182
20 Work Phone: (402) 554-3246
21 Work FAX: (402) 554-5938
22 Email: samyers@unomaha.edu

23 And
24 Iraklis Pipinos, MD
25 University of Nebraska Medical Center
26 Work Phone: 402.559.9549
27 Email: ipipinos@unmc.edu

28
29 **Key Words:** peripheral artery disease, vascular stenosis, vascular narrowing, gait biomechanics,
30 walking

31 **ABSTRACT**

32 **Objective:** Different levels of arterial occlusive disease (aortoiliac, femoropopliteal, multi-level
33 disease) can produce claudication symptoms in different leg muscle groups (buttocks, thighs,
34 calves) in patients with peripheral artery disease (PAD). We tested the hypothesis that different
35 levels of occlusive disease uniquely affect the muscles of PAD legs and produce distinctive
36 patterns in the way claudicating patients walk.

37 **Methods:** 97 PAD patients and 35 healthy controls were recruited. PAD patients were categorized
38 to aortoiliac, femoropopliteal and multi-level disease groups using computerized tomographic
39 angiography. Subjects performed walking trials both pain-free and during claudication and joint
40 kinematics, kinetics, and spatiotemporal parameters were calculated to evaluate the net
41 contribution of the calf, thigh and buttock muscles.

42 **Results:** PAD patients with different levels of arterial occlusions had different patterns of
43 symptoms in their calves, thighs and buttocks. However, no significant biomechanical differences
44 were found between PAD groups during the pain-free conditions with minimal differences
45 between PAD groups in the claudicating state. All statistical differences in the pain-free condition
46 occurred between healthy controls and one or more PAD groups. A discriminant analysis function
47 was able to adequately predict if a subject was a control with over 70% accuracy, but the function
48 was unable to differentiate between PAD groups.

49 **Conclusions:** In-depth gait analyses of claudicating PAD patients indicate that different levels of
50 arterial disease produce symptoms that affect different muscle groups across the lower extremity
51 but impact the function of the leg muscles in a diffuse manner generating similar walking
52 impairments.

53 INTRODUCTION

54 Intermittent claudication is the most common manifestation of peripheral artery disease
55 (PAD)[1]. Claudication is defined as walking-induced, ischemic leg pain that is most commonly
56 described by the patient as severe muscle cramping, tightness, aching, and/or fatigue[2].
57 Claudication results in severely decreased functional ability[3] and quality of life[4] and is
58 associated with increased risk for the occurrence of other cardiovascular related events and
59 mortality[5]–[7].

60 Patients with PAD walk with an abnormal gait pattern compared to healthy, age matched
61 controls[8], [9]. The majority of these gait abnormalities are present from the first step the
62 patients take, well before the onset of claudication, and become more severe when claudication
63 discomfort begins[10], [11]. Research from our group and others has shown that the abnormal
64 gait pattern is characterized by slower walking speed, decreased cadence, increased stance time,
65 and shorter stride lengths compared to healthy, age-matched controls[12]. Furthermore, patients
66 with PAD walk with altered joint angles[12], [13] and reduced joint torques[10], [14] and
67 powers[10], [14], [15] around the ankle, knee, and hip joints compared to their healthy
68 counterparts.

69 Atherosclerotic stenoses/occlusions can occur at any or multiple levels throughout the
70 arterial tree supplying the leg, restricting blood flow to the muscles responsible for movement at
71 the hip, knee, and ankle joints. These blockages are typically grouped into the following general
72 levels: aortoiliac (AI), femoropopliteal (FP), tibial, and multi-level disease (MLD)[16].
73 Aortoiliac disease can produce claudication symptoms in all major muscle groups (calves, thighs
74 and buttocks) of the leg [17], [18]. Femoropopliteal disease can produce claudication symptoms

75 in the muscles of the calves[17]. Tibial disease may also produce claudication symptoms in the
76 muscles of the calf. Multi-level atherosclerosis is associated with vascular narrowing/occlusion
77 in more than one level of the arterial tree of the leg. Patients with MLD tend to have worse
78 hemodynamic compromise, than patients with single level disease, and they can experience
79 claudication symptoms in all major muscle groups of the leg including those of the calves, thighs
80 and buttocks. However, they usually experience claudication pain distal to the most affected
81 arterial segment[18] [19].

82 Arterial blockages and the ischemia and ischemia/reperfusion they generate in the
83 muscles they affect, produce an ischemic myopathy in the legs of PAD patients. At the
84 histological level the principal characteristics of the myopathy are myofiber degeneration and
85 fibrosis of the extracellular matrix and microvessels of the affected muscles[20]–[25], [64]. At
86 the biochemical level the myopathy is characterized by oxidative damage, mitochondrial
87 dysfunction, cytoskeletal disintegration and a characteristic upregulation of cytokines[20], [22],
88 [26]–[31]. The myopathy of PAD in association with exercise-induced ischemia produce the,
89 familiar to all vascular practitioners, abnormal muscle performance and metabolically inefficient
90 walking pattern of claudicating patients[10]–[12], [14], [15], [32]. Because the level of occlusive
91 disease usually determines the muscle group that is affected by the discomfort of claudication, it
92 is possible that disease level may also play a primary role in the patient’s walking biomechanics
93 and determine a patient’s compensation strategies during gait. Specifically, it is likely that
94 different levels of occlusive disease produce ischemia, myopathy, and functional compromise of
95 different muscle groups in the PAD legs which then results in distinctive gait patterns. It is also
96 possible that as different muscle groups are affected, the patient’s muscular and neurological
97 systems respond by alleviating the load placed on the more affected muscle groups while

98 increasing the contribution of less affected muscles in an attempt to reduce pain and improve
99 metabolic efficiency. Investigating the influence of disease level on a patient's gait may provide
100 pivotal information regarding the pathophysiology of claudication and the development of each
101 patient's walking impairments. By identifying if and how the level of vascular stenosis/occlusion
102 affects the contributions of the muscles that move particular joints, and results in specific gait
103 abnormalities in individuals with PAD, clinicians and therapists may be better able to understand
104 the type and degree of functional limitation produced by different patterns of occlusive disease.
105 This knowledge may help with the development of treatment plans that target specific muscles
106 such as the ankle or knee or hip flexors/extensors based on the vascular stenosis/occlusion level
107 and may provide the basis for physical therapy and exercise interventions that are more patient-
108 specific and possibly more effective in rehabilitating each patient's PAD limitations.

109 In this study we tested the hypothesis that the level of arterial stenosis/occlusion would
110 uniquely impair the net muscle contributions, walking pattern and overall walking ability
111 between patients with different levels of disease and compared to healthy controls. More
112 specifically we aimed to determine if different levels of vascular stenosis/ occlusion uniquely
113 affect walking patterns, as described by objective kinematic, kinetic, spatiotemporal gait
114 parameters, and six minute walk distances and by subjective measurements acquired through the
115 Walking Impairment Questionnaire (WIQ) and the Medical Outcomes Study Short Form 36
116 Health Survey (SF-36). Furthermore, we sought to determine if claudicating patients can be
117 classified according to their level of disease based on their pattern of gait impairments.

118

119

120 **METHODS**

121 *Study Participants*

122 Ninety Seven patients (96 males, 1 female) diagnosed with claudication secondary to
123 PAD, age (63.34 ± 6.49 years), height (1.76 ± 0.07 m), and body-mass (87.31 ± 17.22 kg) were
124 recruited from the Nebraska and Western Iowa Veterans Affairs Medical Center and the
125 University of Nebraska Medical Center. Thirty-five healthy controls with similar age ($65.23 \pm$
126 9.51 years), height (1.74 ± 0.08 m), and body-mass (79.90 ± 13.80 kg) were recruited from the
127 community.

128 *Inclusion and Exclusion Criteria*

129 Patient inclusion criteria included the ability to provide written, informed consent for
130 study participation, a history of chronic, exercise-limiting claudication, an ABI ≤ 0.90 at rest[33],
131 [34] and stable blood pressure, lipid, and/or diabetes regimens and risk factor control for six
132 weeks or more. Patient exclusion criteria included ischemic rest pain, tissue loss due to PAD, the
133 presence of acute lower leg ischemia and significant limitations in the ability to walk due to
134 conditions other than claudication such as pathology occurring in the leg (joint, musculoskeletal,
135 neurological), heart, or lungs. Patients were screened and evaluated by one of two board certified
136 vascular surgeons prior to study enrollment. Healthy control participants were excluded for the
137 same exclusion criteria as the PAD population or if they had walking limitations, if they
138 experienced leg pain during walking, or if their ABI values at rest were ≤ 0.90 . All controls were
139 screened by a trained member of the study team measuring systolic pressures at the brachial and
140 pedal arteries using Doppler [6]. Informed consent was obtained from all study participants prior

141 to data collection according to the guidelines of the institutional review boards of the two
142 medical centers.

143 *CTA and determination of level of disease*

144 Patients with PAD underwent computerized tomographic angiography (CTA) of the abdomen,
145 pelvis and lower extremities including delayed imaging. 1.5-mm cross-sectional images were
146 obtained from the lower chest to the toes and were used by one of two board certified vascular
147 surgeons to determine the level of disease[35] [36]. The degree of arterial stenosis was
148 considered minimal if the arterial diameter was decreased by less than 10%, mild if the arterial
149 diameter was decreased by 10 to 30%, moderate if the arterial diameter was decreased by 30% to
150 70%, and severe if the arterial diameter was decreased by more than 70%. A patient was
151 considered as having disease in a segment of his arterial tree if there was evidence of moderate
152 or severe stenosis (30-100% blockage) in one or more arteries of that segment. Patients with
153 minimal (<10% diameter reduction) or mild stenosis (10-30% diameter reduction) in the arteries
154 of a particular segment were considered as not having occlusive disease in that segment.
155 Occlusive disease patterns were described as Aortoiliac (AI, stenosis/occlusion in the aorta, iliac
156 and common femoral arteries), Femoropopliteal (FP, stenosis/occlusion in the superficial femoral
157 and popliteal arteries) and multilevel disease (MLD, Aortoiliac + femoropopliteal disease). A
158 total of 26 (of 97) PAD patients had significant disease that affected one to three of their tibial
159 arteries but all of them had dominant disease in the more proximal AI or FP segments and were
160 analyzed as part of the dominant proximal segment(s) of disease. More specifically, 25 patients
161 (age: 60.67 ± 6.52 years, height: 1.77 ± 0.09 m, body mass: 90.50 ± 14.90 kg) had isolated AI
162 disease. Four patients in the AI group had disease in one of their tibial arteries and the rest had
163 no appreciable tibial disease. Twenty-three patients (age: 63.57 ± 6.69 years, height: 1.75 ± 0.08

164 m, body mass: 84.20 ± 19.66 kg) had isolated FP disease. Four patients in the FP group had
165 disease in one, one had disease in two and two had disease in all three tibial arteries while the
166 rest had no appreciable tibial disease. Forty-nine patients (age: 64.55 ± 6.11 years, height; $1.75 \pm$
167 0.05 m, body mass: 87.14 ± 17.17 kg) had MLD (combination of AI and FP disease). Eleven
168 patients in the MLD group had disease in one, three had disease in two and one in all three tibial
169 arteries while the rest had no appreciable tibial disease.

170 ***Experimental Procedure and Data Collection***

171 Prior to data collection, 27 retro-reflective markers were placed at specific anatomical
172 locations on each participant's lower limbs utilizing the marker systems of Vaughan and
173 Nigg[37], [38]. To capture kinematic and kinetic gait parameters, each study participant was
174 instructed to walk at their preferred walking speed over a 4.5-meter walkway containing in-
175 ground force platforms. Participants with PAD performed overground walking trials in both a
176 pain free and claudicating state. Each subject's most affected leg based on lowest ABI value was
177 used for analysis. During the pain free condition, a one-minute rest period was required between
178 walking trials to ensure the absence of claudication; more rest was required if the participant
179 indicated pain was present. To induce the claudicating state, each participant with PAD
180 performed a six-minute walk test. For this test, participants were instructed to cover as much
181 distance as possible in six minutes, walking around two cones placed 50 feet apart inside the
182 laboratory. If the participant desired, they were able to rest during the test, but the six-minute
183 timer continued to run. Confirmation that participants were experiencing claudication was
184 obtained prior to performing the overground claudication trials. During the claudication
185 condition, study participants were not given a one-minute rest between trials, and they confirmed
186 the presence of claudication pain prior to beginning each trial.

187 ***Data Analysis***

188 *Quality of life measures.* Overall health and physical function were assessed using the
189 WIQ[39] and SF-36[40]. The WIQ is a disease-specific questionnaire validated in patients with
190 intermittent claudication. It consists of four subcategories: pain, walking distance, walking
191 speed, and stair climbing ability. The SF-36 consists of eight health domains: physical function,
192 limitation due to physical health, limitation due to emotional health, energy/vitality, general
193 mental health, bodily pain, social function, and overall general health. The SF-36 has been
194 extensively evaluated and tested with a variety of populations and is able to distinguish between
195 groups of varying health status[41]. Both scales range from 0 to 100, with 100 being the higher
196 functioning/more positive health outcome score.

197 *Quantitative biomechanics measures.* The participants' lower extremity three-
198 dimensional kinematics were collected using a Motion Analysis eight-camera motion capture
199 system (Motion Analysis Corp, Santa Rosa, CA) sampling at 60Hz. Kinetic data were acquired
200 using one Kistler piezoelectric force platform (Kistler North America, Amherst, NY) sampling at
201 600Hz. Motion capture data were filtered using a low pass Butterworth filter with a cutoff
202 frequency of 5Hz. For the kinematic and kinetic data, a total of five clean foot contacts were
203 collected and averaged for each study participant in each walking condition. A clean foot contact
204 was defined as a step in which the foot in stance phase only came in contact with one force
205 platform and no other contacts occurred on that platform during the walking trial.
206 Spatiotemporal gait parameters were calculated by averaging data from five of the overground
207 walking trials. Because spatiotemporal gait parameters were not initially analyzed for this data,
208 two of the participants in the FP group and three healthy controls did not take enough steps for
209 spatiotemporal characteristics to be calculated from each of the walking trials. Data were

210 exported and processed using Cortex C-Motion Capture system (Motion Analysis Corporation,
211 Santa Rosa, CA), Visual 3D (Germantown, MD, USA), and personalized MATLAB (The
212 Mathworks, Inc., Natick, MA, USA) codes.

213 Joint kinematics and kinetics were calculated in the sagittal plane during the stance phase
214 of walking. The stance phase can further be divided into three distinct stages: weight acceptance,
215 single limb support, and push-off. An inverse dynamics solution was performed to calculate joint
216 torques and powers from joint kinematics and ground reaction force data. Only data from each
217 patient's most affected leg were analyzed, and control participants were distributed to match the
218 ratio of right to left legs that were analyzed from the patients with PAD. Torque and power data
219 were normalized to each participant's body mass.

220 A canonical linear discriminant function analysis (i.e., discriminant analysis) was
221 performed to determine if differences in gait parameters could be used to distinguish between
222 different levels of disease and healthy controls. Data were checked for multicollinearity to reduce
223 the amount of mutual information in the model by running a bivariate Pearson's correlation for
224 both the pain and pain free data. During the pain free condition ankle plantarflexor torque, knee
225 flexion torque, hip extension torque, ankle power absorption during weight acceptance, ankle
226 power absorption during single limb support, ankle power generation during push-off, knee
227 power generation during single limb support, hip power generation during weight acceptance,
228 hip power absorption during single limb support, hip power generation during push-off, ankle
229 range of motion, hip range of motion, stride length, and stance time were included in the
230 analysis. During the pain condition, ankle dorsiflexion torque, knee flexion torque, hip extension
231 torque, hip flexion torque, ankle power absorption during weight acceptance, ankle power
232 absorption during single limb support, ankle power generation during push-off, hip power

233 generation during weight acceptance, knee power absorption during push-off, ankle range of
234 motion, knee range of motion, and stride time were included in the analysis.

235 *Statistical Analysis*

236 Independent, one-way analysis of variance (ANOVA) tests were used to identify
237 differences between participant groups (controls, AI, FP, MLD) for SF-36 subscale scores, WIQ
238 subscale scores, and quantitative gait measures. A significant main effect indicates one or more
239 significant differences between two or more of the four groups being compared. For variables
240 with significant main effects, Bonferroni post hoc analyses were performed when necessary to
241 determine which groups were significantly different from each other. Independent samples t-tests
242 were used to compare controls to all PAD patients pooled in a single group. A discriminant
243 analysis was performed for each walking condition to determine if gait impairments were able to
244 distinguish between patients with different levels of disease and healthy controls and determine
245 which gait variables were most useful in this calculation. All analyses were performed using
246 SPSS 23 statistical software (SPSS Inc., Chicago, Ill) with an alpha level set to 0.05.

247

248

249

250

251

252

253

254

255

256 **RESULTS**

257 *Demographics*

258 Demographic and anthropometric data for each participating group can be found in Table

259 I. There was not a significant between-groups effect of age, height, body mass, or body mass

260 index. Ankle brachial index was significantly different between patient groups for both the most

261 affected ($p < 0.001$) and least affected leg ($p < 0.001$). Patients with MLD had significantly

262 lower ABI values in both the most and least affected legs compared to the AI (most affected: $p <$

263 0.001 , least affected: $p < 0.001$) and FP (most affected: $p = 0.019$, least affected: $p = 0.015$)

264 groups. Of the 25 patients with AI disease eight had mild, eleven minimal, and six no FP

265 occlusive disease. Three of the patients with AI disease presented with calf claudication, five

266 with thigh and calf, six with buttock and calf, nine with buttock, thigh, and calf, and two with

267 buttock and thigh symptoms. Of the 23 patients with FP disease eleven had mild, nine minimal,

268 and three no AI occlusive disease (two of these three patients had mildly ectatic AI segment). All

269 23 patients with FP disease presented with calf only claudication. All 49 MLD patients had

270 combination of AI and FP disease. Fifteen presented with calf claudication, thirteen with thigh

271 and calf, six with buttock and calf, fourteen with buttock, thigh, and calf, and one with buttock-

272 only symptoms.

273 INSERT TABLE I ABOUT HERE

274 *Questionnaire comparisons between healthy controls and PAD groups*

275 When comparing WIQ subscale scores across participant groups, there were significant

276 main effects for each of the four subscale categories (WIQ Pain: $p < 0.001$, WIQ Distance: $p <$

277 0.001 , WIQ Speed: $p < 0.001$, WIQ Stairs: $p < 0.001$; Table II). Healthy control participants had

278 significantly higher WIQ scores across all four subscales when independently compared to each
279 patient group (Table II).

280 INSERT TABLE II ABOUT HERE

281 When comparing SF-36 subscale scores across participant groups, significant main
282 effects were present for physical function ($p < 0.001$), limitations due to physical health ($p <$
283 0.001), limitations due to emotional health ($p = 0.002$), energy ($p < 0.001$), emotional health ($p <$
284 0.001), pain ($p < 0.001$), social function ($p < 0.001$) and general function ($p < 0.001$; Table III).
285 Post-hoc tests revealed control participants had significantly higher SF-36 scores in independent
286 comparisons to each level of disease group for all subscales except the emotional health subscale
287 where the AI group did not differ from healthy controls (Table III). This indicates healthy
288 controls had better functioning than all PAD groups for nearly all health domains assessed by the
289 SF-36. In the emotional health subscale, the AI group scored higher than the MLD group ($p =$
290 0.004), indicating better emotional health for those with AI level disease. In the pain subscale the
291 MLD group scored significantly higher than the FP group ($p = 0.009$), meaning the MLD group
292 subjectively had less pain than the FP group.

293 INSERT TABLE III ABOUT HERE

294 *Pain free walking: healthy controls versus PAD groups*

295 There were significant main effects between participant groups for kinematic and kinetic
296 gait parameters when walking in the pain-free condition for 12 of the 18 biomechanics measures
297 (ankle dorsiflexor torque: $p = 0.004$, knee extensor torque: $p = 0.006$, hip extension torque: $p <$
298 0.001 , hip flexor torque: $p < 0.001$, ankle power absorption during weight acceptance: $p < 0.001$,
299 ankle power generation during push-off: $p < 0.001$, knee power absorption during weight

300 acceptance: $p = 0.013$, knee power generation during single limb support: $p = 0.002$, knee power
301 absorption during push-off: $p < 0.001$, hip power absorption during single limb support: $p =$
302 0.001 , hip power generation during push-off: $p < 0.001$, hip range of motion: $p = 0.003$; Table
303 IV). The six variables that did not have significant differences during pain free walking included:
304 ankle plantarflexor torque during push-off, knee flexor torque during single limb support, ankle
305 power absorption during single limb support, hip power generation during weight acceptance,
306 ankle range of motion, and knee range of motion (Table IV). There were similar significant main
307 effects for spatiotemporal gait parameters during pain free walking, with seven of the eight
308 dependent variables demonstrating significant differences (step length: $p < 0.001$, stride length: p
309 < 0.001 , walking velocity: $p < 0.001$, stance time: $p < 0.001$, stride time: $p = 0.002$, step width: p
310 $= 0.006$, cadence: $p = 0.001$) Only swing time did not have a significant main effect during pain
311 free walking (Table V).

312 The post-hoc analysis revealed that all differences occurred between one or more level of
313 disease groups and healthy controls. Bonferroni post hoc analyses indicated no differences for
314 kinematic, kinetic, or spatiotemporal gait parameters between PAD level of disease groups when
315 walking in the pain free condition. Of the total 26 gait comparisons (18 kinematic/kinetic and 8
316 spatiotemporal), the differences between healthy controls and all PAD groups occurred for 20 of
317 26 variables, patients with AI level disease for 12 of 26 variables, patients with FP for 15 of 26
318 variables, and patients with MLD for 20 of 26 variables (Tables IV and V).

319 INSERT TABLES IV AND V ABOUT HERE

320 *Pain walking: healthy controls versus PAD groups*

321 When walking in the pain condition, there were significant main effects of participant
322 group for 14 of 18 kinematic and kinetic gait parameters (ankle dorsiflexor torque: $p < 0.001$,
323 ankle plantarflexor torque: $p < 0.001$, knee extensor torque: $p = 0.008$, hip extension torque: $p <$
324 0.001 , hip flexor torque: $p < 0.001$, ankle power absorption during weight acceptance: $p < 0.001$,
325 knee power absorption during weight acceptance: $p = 0.007$, knee power generation during
326 single limb support: $p = 0.005$, hip power absorption during single limb support: $p = 0.003$, ankle
327 power generation during push-off: $p < 0.001$, knee power absorption during push-off: $p < 0.001$,
328 hip power generation during push-off: $p < 0.001$, ankle range of motion: $p = 0.002$, hip range of
329 motion: $p < 0.001$). The four variables that did not show a significant main effect were knee
330 flexor torque during single limb support, hip power generation during weight acceptance, ankle
331 power absorption during single limb support, and knee range of motion (Table VI). There were
332 also significant main effects for eight spatiotemporal gait parameters (step length: $p < 0.001$,
333 stride length: $p < 0.001$, walking velocity: $p < 0.001$, stance time: $p < 0.001$, stride time: $p =$
334 0.006 , step width: $p = 0.009$) Swing time and cadence did not show a significant main effect
335 (Table VII).

336 Bonferroni post hoc analyses indicated no differences for kinematic, kinetic, or
337 spatiotemporal gait parameters between any PAD level of disease groups when walking in the
338 pain condition except two differences. Those differences include the MLD group, which had a
339 significantly larger ankle power absorption during weight acceptance compared to the FP group
340 ($p = 0.003$), and the AI group produced significantly more ankle power during push-off
341 compared to the MLD group ($p = 0.019$). All other differences occurred between one or more
342 level of disease groups and healthy controls. The controls versus all PAD group comparison
343 yielded differences in 21 of 26 gait variables. Controls were significantly different than patients

344 with AI level disease for nine of 26 variables, patients with FP disease for 13 of 26 variables, and
345 patients with MLD for 19 of 26 variables (Tables VI and VII).

346 *Classifying subject group from gait impairments*

347 In the pain free condition, a total of 99 study participants were included in the
348 discriminant analysis. Thirty-three subjects were removed from the total sample of 132 due to
349 the inability to calculate spatiotemporal data or if they were considered to be outliers. Significant
350 connections between the studied gait variables and subject grouping were found ($p = 0.011$,
351 Wilk's Lambda = 0.478). The classification results indicated the discriminant function correctly
352 classified 56.6% of subjects into the correct subject group. The analysis was most accurate in
353 predicting healthy controls with a 76.0% classification accuracy. This was followed by MLD,
354 AI, and FP with a 65.7%, 36.8% and 35.0% classification accuracy respectively. The gait
355 parameter with the most significant contribution to the prediction of subject group in the pain
356 free condition was ankle power generation with a standardized canonical discriminant function
357 coefficient of 0.504. The canonical correlation for this function was 0.629.

358 In the pain condition, a total of 105 study participants were included in the discriminant
359 analysis. Similar to the pain-free conditions, 27 subjects were removed from the total 132
360 subjects due to the inability to calculate spatiotemporal data or if they were considered to be
361 outliers. Significant connections between the studied gait variables and subject grouping were
362 found ($p < 0.001$, Wilk's Lambda = 0.424). The classification results indicated the discriminant
363 function correctly classified 70.5% of subjects into the correct subject group. The analysis was
364 most accurate in predicting the MLD group with an 88.6% classification accuracy. This was
365 followed by controls, FP, and AI with a classification accuracy of 83.3%, 44.4% and 36.8%

366 respectively. The gait parameter with the most significant contribution to the prediction of
367 subject group in the pain condition was ankle power generation with a standardized canonical
368 discriminant function coefficient of -0.539. The canonical correlation for this function was 0.658.

369

370 **DISCUSSION**

371 Our data using advanced biomechanical analyses and standard clinical and quality of life
372 assessments, indicate that different levels of arterial disease present with very different patterns
373 of symptoms affecting the different muscle groups of the lower extremity but produce similar
374 degrees of impairments across all muscle groups of the leg and in the walking patterns and
375 walking distances of claudicating PAD patients. We found that PAD patients with different
376 levels of vascular stenosis/occlusion have very similarly affected gait patterns (as described by
377 kinematic, kinetic, and spatiotemporal gait parameters) and walking distances (measured with
378 six-minute walk test) and very similar subjective impairments (measured with WIQ and SF-36).
379 Patients with AI, FP and MLD disease all had similarly impaired biomechanics, compared to
380 control, around their ankle, knee and hip joints (the muscle groups flexing and extending the
381 ankle, knee and hip are similarly impaired in all PAD groups). None of the investigated
382 biomechanical parameters differed between level of disease groups in the pain free walking
383 condition, with minimal differences occurring in the claudicating condition. Moreover, when
384 trying to determine if patients can be classified according to their level of disease based on gait
385 impairments, and if quality of life information acquired through the WIQ and SF-36, differed
386 across groups of patients with different levels of disease, we found that the model performed
387 well in identifying healthy controls in both the pain (83.3% classification accuracy) and pain

388 free (76.0% classification accuracy) conditions and that the model can also accurately classify
389 individuals in the MLD group during the pain condition (88.6% classification accuracy), but had
390 trouble differentiating between PAD subject groups in all other scenarios. Previous work has
391 shown that gait impairments are present from the first steps a PAD patient takes while walking
392 pain-free and are augmented when the patient starts experiencing claudication symptoms [10],
393 [11]. This augmentation of walking impairments, especially in what is traditionally the lowest
394 functioning group (MLD)[19], may help explain why the discriminant analysis was more
395 accurate in identifying subject groupings during the pain condition compared to pain-free
396 walking. The conclusion of no differences between level of disease groups is reinforced by the
397 fact that all WIQ subscales scores were statistically similar between PAD groups. The SF-36
398 scores were also similar across level of disease groups with the only differences identified being
399 in the subscales of pain between the FP and MLD groups and emotional health between the AI
400 and MLD groups.

401 The results of the current study are not in accord with our hypothesis that different levels
402 of occlusive disease uniquely affect the muscle contributions within the PAD legs and therefore
403 produce distinctive differences in the way claudicating patients walk. Although it may be
404 understandable that claudication produced by occlusions that are similar in hemodynamic
405 significance impair walking distances and quality of life parameters in a similar fashion
406 irrespective of the level of the arterial tree involved, it is difficult to explain how this would also
407 be the case for gait biomechanics. For example, it is difficult to understand how a patient with
408 FP disease presenting with calf claudication can have similarly affected knee and hip
409 biomechanics reflecting similarly compromised thigh and buttock muscle contributions as a
410 patient with AI or MLD disease presenting with calf, thigh and buttock claudication. However,

411 this is exactly what our data demonstrate. More specifically all patients with FP disease present
412 with claudication symptoms affecting only their calves while 22 out of 25 AI patients and 34 of
413 49 MLD patients present with claudication symptoms that also affect the thigh and/or buttock
414 musculature, yet gait biomechanics were similar across the three groups. Our findings on level of
415 symptoms confirms the well-known fact that different levels of arterial occlusive disease produce
416 symptoms in different muscle groups (calves, thighs, buttocks) of the leg [17], [18] which led us
417 to theorize that different levels of occlusive disease produce ischemia, myopathy and functional
418 compromise of different muscle groups and this would result in distinctive biomechanical
419 patterns around the ankle, knee and hip joints. The absence of difference in gait biomechanical
420 patterns was surprising to us and raises several considerations that may explain our findings.

421 A possible explanation may be that AI, FP and MLD all affect the calf and foot of the
422 patient and that the affected foot and calf dominate the biomechanical behavior of the entire leg
423 [42]. This can lead to ankle movement impacting knee and hip mechanics. The stance phase of
424 walking is a closed chain movement, so movement impairments at the ankle must produce a
425 corresponding response (and possibly an impairment) at the knee and/or hip. Additionally, the
426 biarticular nature of certain hamstring, quadricep, and calf muscles, makes it likely that pain in
427 the calves, thigh, or buttocks can impact mechanics at more than one joint.

428 It is also possible that what we consider to be hemodynamically insignificant (<30%
429 diameter reduction) disease in an arterial segment is a significant contributor to the functional
430 deterioration of the muscles supplied by this arterial segment. This may be because the disease
431 becomes hemodynamically significant (either pressures drop or flow patterns change across the
432 segment) when exercise initiates higher flows through the diseased segment, or because the
433 atherosclerotic plaques (even though they are mild or minimal) produce cytokines, reactive

434 oxygen species and pro-inflammatory products that then reach and adversely affect the
435 corresponding muscle groups [43], [44]. This possibility may be of particular interest since the
436 vast majority of patients with FP disease have atherosclerotic changes in their AI segment
437 (eleven had mild, nine minimal and only three had no occlusive disease) and similarly, the
438 majority of AI patients have atherosclerotic changes in their FP segment (eight had mild, eleven
439 minimal and six no femoropopliteal occlusive disease) even though these changes are not
440 hemodynamically significant (<30%). Essentially, one of the most important findings of our
441 study is the very low prevalence of strictly one-level of PAD in claudicating patients. Our data
442 suggest that PAD is an atherosclerotic process that presents as multilevel disease with certain
443 arterial segments becoming involved with more hemodynamically significant stenoses than
444 others and this multilevel disease affects the ischemic legs of PAD patients in a multilevel
445 fashion impairing the performance of all leg muscles at the buttock, thigh, and calf level.

446 It is also possible that occlusive disease in a segment of the arterial tree changes the flow
447 patterns in the segment above it and that such disturbed flow patterns may affect the health of the
448 endothelium and all the layers of the arterial wall of the seemingly “normal” arterial segment and
449 the muscles that are perfused by the segment. Related to this is the recently described increase in
450 arterial stiffness in the arteries of PAD patients[45]–[47]. This may be promoted by disturbed
451 flow which stimulates pro-inflammatory responses from endothelial cells and promotes
452 atherosclerotic remodeling of affected arteries through lipid accumulation and elastin
453 degradation[46]. The work by Abraham et al. supports this possibility because it demonstrates a
454 substantial decrease in the resting and post exercise transcutaneous oxygen saturation of the skin
455 over the buttocks both in patients with AI disease but also in a large number of patients without
456 AI disease[48], [49].

457 Finally, while it is important to focus on the downstream damage PAD produces to the tissues of
458 the affected lower limbs (due to ischemia and ischemia/reperfusion of the leg) we should also
459 consider the, thus far poorly explored, effects of PAD to the rest of the body (mediated through
460 the activation of metabolic, neural, or inflammatory pathways) as this may also explain some of
461 our findings. In this process the ischemic limb distributes and communicates to the rest of the
462 body, the adverse ischemic events it suffers several times during the day, every time the patient
463 experiences leg ischemia with or without associated claudication symptoms. In this process a
464 patient with FP disease and an ischemic calf can experience pathological changes and decreased
465 performance of the ipsilateral non-ischemic thigh or pelvic musculature but also damage to other
466 limbs and organs of the body. This may be an important pathway explaining how PAD can
467 produce the increased morbidity and mortality that is so well documented for PAD patients [5]–
468 [7]. The best evidence for a systemic effect of PAD comes from work showing that a single bout
469 of exercise of the PAD legs produces a significant increase of biomarkers of oxidative stress
470 (increased malondialdehyde, consumption of anti-oxidants)[50], increased inflammatory cells
471 (white blood cells and neutrophils)[51], [52] and increased inflammatory cytokines
472 (thromboxane, p-selectin, von Willebrand factor) in the blood and a significant activation of the
473 sympathetic system of PAD patients. Of note, the group of Sinoway and Cauffman have shown
474 in several elegant studies that it takes a few, low-intensity, contractions of the posterior calf
475 muscles of PAD patients to produce significant sympathetic system activation and adverse
476 effects on physiologic parameters like the heart rate, blood pressure and coronary and renal
477 artery blood flow[53]–[55]. It is possible that sympathetic system activation by ischemia of the
478 calf can adversely affect the blood flow and the health of the thighs and buttocks. It is likely that
479 the increased local production of anaerobic metabolites, reactive oxygen species, and cytokines

480 is a key mediator for the activation of the sympathetic loops that originate in the ischemic leg
481 [56], [57]. These loops convey the injurious information to the brain, the limb itself, and the rest
482 of body including limbs and organs [58].

483 Ankle power generation at push-off was the most significant contributor in determining
484 subject classification (control versus PAD including AI, FP, or MLD) in both the pain and pain
485 free conditions. This is likely due to the importance of the ankle plantarflexors in propelling the
486 individual forward during walking. The plantarflexor muscles contribute approximately 50% of
487 the positive work on the body's center of mass during propulsion and more mechanical power
488 than the hip and knee joints combined[42], [59]–[61]. Similar to previous studies, our results
489 indicate patients with PAD display significantly lower power and torque outputs at the ankle
490 compared to healthy controls, with augmented differences after the onset of claudication[10],
491 [11], [14], [15], [62]. However, still no differences between patient groups were observed for
492 this variable. Although all PAD groups had vascular stenosis/occlusion at or above the knee
493 joint, resulting in all groups experiencing inadequate blood flow to the plantarflexor muscles,
494 research has shown oxygen delivery to the muscles is not the only limiting factor in exercise
495 performance for individuals with PAD[63]. Our group and others have extensively described that
496 atherosclerotic blockages produce a state of ischemia and ischemia/reperfusion in the PAD legs
497 which initiates oxidative stress/damage, mitochondrial dysfunction and cytokine upregulation,
498 producing injury to all tissues including muscles, nerves, skin, and subcutaneous tissues [20],
499 [31], [64]. Accumulating injury in the leg leads to progressive damage of muscle structure and
500 function which in association with exercise-induced ischemia produce the limitation in walking
501 ability known as claudication. The work of several laboratories including our own has

502 demonstrated that this myopathy is closely related to leg function, daily activity, quality of life
503 and mortality of PAD patients [7], [65]–[68].

504 One possible limitation to this study is how level of disease was assigned to each
505 participant. Participants were assigned to a disease group based on the level of the arterial tree
506 which had significant stenosis/occlusion (>30% diameter reduction) as determined by vascular
507 surgeons using computerized tomographic angiographic imaging[35] [36]. Many of these
508 participants had atherosclerotic disease in other areas of the leg but this disease was minimal
509 (less than 10% diameter reduction) or mild (less than 30% diameter reduction). However, given
510 the study results, the authors do not believe this could have changed the results of the study given
511 no differences were found between any of the PAD groups.

512 **CONCLUSION**

513 Our data using advanced biomechanical analyses and standard clinical and quality of life
514 assessments, indicate that different levels of arterial disease present with symptoms affecting
515 different muscle groups of the lower extremity, but produce similar degrees of dysfunction in all
516 muscle groups of the leg and in the walking patterns, distances, and impairments of PAD patients
517 with claudication. PAD affects claudicating legs in a diffuse manner irrespective of the level of
518 the arterial tree primarily involved. Several pathophysiologic parameters that have to do with the
519 true nature of PAD as a multilevel disease and its complicated hemodynamics, neuropathy,
520 myopathy, and systemic effects will need to be further researched to understand the diffuse
521 manner in which PAD affects the legs of claudicating patients.

522

Acknowledgements

523 This work was supported by grants from the National Institute of Health (R01AG034995,
524 R01HD090333, R01AG049868) and the United States Department of Veterans Affairs
525 Rehabilitation Research and Development Service (I01RX003266).

526 References

- 527 [1] M. H. Criqui and V. Aboyans, “Epidemiology of peripheral artery disease,” *Circ. Res.*,
528 vol. 116, no. 9, pp. 1509–1526, 2015.
- 529 [2] W. R. Hiatt *et al.*, “Atherosclerotic peripheral vascular disease symposium II:
530 nomenclature for vascular diseases,” *Circulation*, vol. 118, no. 25, pp. 2826–2829, 2008.
- 531 [3] H. S. Khaira, R. Hanger, and C. P. Shearman, “Quality of life in patients with intermittent
532 claudication,” *Eur. J. Vasc. Endovasc. Surg.*, vol. 11, no. 1, pp. 65–69, 1996.
- 533 [4] J. P. Pell, “Impact of intermittent claudication on quality of life,” *Eur. J. Vasc. Endovasc.*
534 *Surg.*, vol. 9, no. 4, pp. 469–472, 1995.
- 535 [5] M. H. Criqui *et al.*, “Mortality over a period of 10 years in patients with peripheral arterial
536 disease,” *N. Engl. J. Med.*, vol. 326, no. 6, pp. 381–386, 1992.
- 537 [6] A. B. Newman *et al.*, “Ankle-arm index as a marker of atherosclerosis in the
538 Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research
539 Group,” *Circulation*, vol. 88, no. 3, pp. 837–845, 1993.
- 540 [7] J. R. Thompson *et al.*, “Protein concentration and mitochondrial content in the
541 gastrocnemius predicts mortality rates in patients with peripheral arterial disease,” *Ann.*
542 *Surg.*, vol. 261, no. 3, pp. 605–610, 2015.
- 543 [8] J. D. McCamley *et al.*, “Gait Mechanics Differences Between Healthy Controls and
544 Patients With Peripheral Artery Disease After Adjusting for Gait Velocity Stride Length
545 and Step Width,” *J. Appl. Biomech.*, pp. 1–19, 2018.
- 546 [9] S. A. Myers, B. C. Applequist, J. M. Huisinga, I. I. Pipinos, and J. M. Johanning, “Gait
547 kinematics and kinetics are affected more by peripheral arterial disease than age,” *J.*
548 *Rehabil. Res. Dev.*, vol. 53, no. 2, p. 229, 2016.

- 549 [10] P. Koutakis *et al.*, “Abnormal joint powers before and after the onset of claudication
550 symptoms,” *J. Vasc. Surg.*, vol. 52, no. 2, pp. 340–347, 2010.
- 551 [11] M. M. Scott-Pandorf, N. Stergiou, J. M. Johanning, L. Robinson, T. G. Lynch, and I. I.
552 Pipinos, “Peripheral arterial disease affects ground reaction forces during walking,”
553 *Journal of Vascular Surgery*, vol. 46, no. 3. pp. 491–499, 2007, doi:
554 [//doi.org/10.1016/j.jvs.2007.05.029](https://doi.org/10.1016/j.jvs.2007.05.029).
- 555 [12] R. G. Crowther, W. L. Spinks, A. S. Leicht, F. Quigley, and J. Golledge, “Relationship
556 between temporal-spatial gait parameters, gait kinematics, walking performance, exercise
557 capacity, and physical activity level in peripheral arterial disease,” *J. Vasc. Surg.*, vol. 45,
558 no. 6, pp. 1172–1178, 2007.
- 559 [13] R. Celis, I. I. Pipinos, M. M. Scott-Pandorf, S. A. Myers, N. Stergiou, and J. M.
560 Johanning, “Peripheral arterial disease affects kinematics during walking,” *J. Vasc. Surg.*,
561 vol. 49, no. 1, pp. 127–132, 2009.
- 562 [14] P. Koutakis, I. I. Pipinos, S. A. Myers, N. Stergiou, T. G. Lynch, and J. M. Johanning,
563 “Joint torques and powers are reduced during ambulation for both limbs in patients with
564 unilateral claudication,” *J. Vasc. Surg.*, vol. 51, no. 1, pp. 80–88, 2010.
- 565 [15] S. R. Wurdeman, P. Koutakis, S. A. Myers, J. M. Johanning, I. I. Pipinos, and N. Stergiou,
566 “Patients with peripheral arterial disease exhibit reduced joint powers compared to
567 velocity-matched controls,” *Gait Posture*, vol. 36, no. 3, pp. 506–509, 2012.
- 568 [16] M. R. Jaff *et al.*, “An update on methods for revascularization and expansion of the TASC
569 lesion classification to include below-the-knee arteries: a supplement to the Inter-Society
570 Consensus for the Management of Peripheral Arterial Disease (TASC II),” *Ann. Vasc.*
571 *Dis.*, vol. 8, no. 4, pp. 343–357, 2015.

- 572 [17] J. Olin, B. S.-M. C. Proceedings, and undefined 2010, “Peripheral artery disease: current
573 insight into the disease and its diagnosis and management,” *Elsevier*, Accessed: Jun. 04,
574 2020. [Online]. Available:
575 <https://www.sciencedirect.com/science/article/pii/S0025619611601742>.
- 576 [18] J. F. Lau, M. D. Weinberg, and J. W. Olin, “Peripheral artery disease. Part 1: Clinical
577 evaluation and noninvasive diagnosis,” *Nature Reviews Cardiology*, vol. 8, no. 7. Nature
578 Publishing Group, pp. 405–418, Jul. 31, 2011, doi: 10.1038/nrcardio.2011.66.
- 579 [19] A. Almahameed, “Peripheral arterial disease: Recognition and medical management
580 Access Site Management View project,” *Artic. Clevel. Clin. J. Med.*, 2006, doi:
581 10.3949/ccjm.73.7.621.
- 582 [20] I. I. Pipinos *et al.*, “The myopathy of peripheral arterial occlusive disease: Part 2.
583 Oxidative stress, neuropathy, and shift in muscle fiber type,” *Vascular and Endovascular
584 Surgery*, vol. 42, no. 2. pp. 101–112, Apr. 2008, doi: 10.1177/1538574408315995.
- 585 [21] P. Koutakis *et al.*, “Abnormal myofiber morphology and limb dysfunction in
586 claudication,” *J. Surg. Res.*, vol. 196, no. 1, pp. 172–179, Jun. 2015, doi:
587 10.1016/j.jss.2015.02.011.
- 588 [22] D. J. Weiss *et al.*, “Oxidative damage and myofiber degeneration in the gastrocnemius of
589 patients with peripheral arterial disease,” *J. Transl. Med.*, vol. 11, no. 1, Sep. 2013, doi:
590 10.1186/1479-5876-11-230.
- 591 [23] D. M. Ha *et al.*, “Transforming growth factor-beta 1 produced by vascular smooth muscle
592 cells predicts fibrosis in the gastrocnemius of patients with peripheral artery disease,” *J.
593 Transl. Med.*, vol. 14, no. 1, p. 39, Feb. 2016, doi: 10.1186/s12967-016-0790-3.
- 594 [24] C. J. Mietus *et al.*, “Abnormal Microvascular Architecture, Fibrosis, and Pericyte

- 595 Characteristics in the Calf Muscle of Peripheral Artery Disease Patients with Claudication
596 and Critical Limb Ischemia,” *J. Clin. Med.*, vol. 9, no. 8, p. 2575, Aug. 2020, doi:
597 10.3390/jcm9082575.
- 598 [25] G. Cong, X. Cui, R. Ferrari, I. Pipinos, ... G. C.-J. of C., and undefined 2020, “Fibrosis
599 Distinguishes Critical Limb Ischemia Patients from Claudicants in a Transcriptomic and
600 Histologic Analysis,” *mdpi.com*, Accessed: Aug. 28, 2021. [Online]. Available:
601 <https://www.mdpi.com/917494>.
- 602 [26] I. I. Pipinos *et al.*, “Mitochondrial defects and oxidative damage in patients with
603 peripheral arterial disease,” *Free Radic. Biol. Med.*, vol. 41, no. 2, pp. 262–269, Jul. 2006,
604 doi: 10.1016/j.freeradbiomed.2006.04.003.
- 605 [27] K. I. Makris *et al.*, “Mitochondriopathy of peripheral arterial disease,” *Vascular*, vol. 15,
606 no. 6. pp. 336–343, Nov. 2007, doi: 10.2310/6670.2007.00054.
- 607 [28] P. Koutakis, D. Weiss, D. Miserlis, V. S.-R. biology, and undefined 2014, “Oxidative
608 damage in the gastrocnemius of patients with peripheral artery disease is myofiber type
609 selective,” *Elsevier*, Accessed: Dec. 30, 2020. [Online]. Available:
610 <https://www.sciencedirect.com/science/article/pii/S2213231714000858>.
- 611 [29] P. Koutakis, D. Miserlis, ... S. M.-... of H. &, and undefined 2015, “Abnormal
612 accumulation of desmin in gastrocnemius myofibers of patients with peripheral artery
613 disease: associations with altered myofiber morphology and density,”
614 *journals.sagepub.com*, vol. 63, no. 4, pp. 256–269, Apr. 2015, doi:
615 10.1369/0022155415569348.
- 616 [30] G. Brevetti, G. Giugliano, L. Brevetti, and W. R. Hiatt, “Inflammation in peripheral artery
617 disease,” *Circulation*, vol. 122, no. 18. pp. 1862–1875, Nov. 02, 2010, doi:

- 618 10.1161/CIRCULATIONAHA.109.918417.
- 619 [31] G. Casale, J. Thompson, L. Carpenter, et al., “Cytokine signature of inflammation
620 mediated by autoreactive Th-cells, in calf muscle of claudicating patients with Fontaine
621 stage II peripheral artery disease,” *Transl Res*, vol. Feb, no. 228, pp. 94-108, 2020, doi
622 10.1016/j.trsl.2020.08.008.
- 623 [32] A. W. Gardner, R. M. Ritti-Dias, J. A. Stoner, P. S. Montgomery, K. J. Scott, and S. M.
624 Blevins, “Walking economy before and after the onset of claudication pain in patients
625 with peripheral arterial disease,” *J. Vasc. Surg.*, vol. 51, no. 3, pp. 628–633, 2010.
- 626 [33] V. Aboyans *et al.*, “Measurement and interpretation of the ankle-brachial index: a
627 scientific statement from the American Heart Association,” *Circulation*, vol. 126, no. 24,
628 pp. 2890–2909, 2012.
- 629 [34] L. Norgren, W. R. Hiatt, J. A. Dormandy, M. R. Nehler, K. A. Harris, and F. G. R.
630 Fowkes, “Inter-society consensus for the management of peripheral arterial disease
631 (TASC II),” *J. Vasc. Surg.*, vol. 45, no. 1, pp. S5–S67, 2007.
- 632 [35] D. Fleischmann, R. L. Hallett, and G. D. Rubin, “CT angiography of peripheral arterial
633 disease,” *J. Vasc. Interv. Radiol.*, vol. 17, no. 1, pp. 3–26, 2006.
- 634 [36] J. F. Whelan, M. H. Barry, and J. D. Moir, “Color flow Doppler ultrasonography:
635 comparison with peripheral arteriography for the investigation of peripheral vascular
636 disease,” *J. Clin. ultrasound*, vol. 20, no. 6, pp. 369–374, 1992.
- 637 [37] C. L. Vaughan, B. L. Davis, and C. O. Jeremy, “Dynamics of human gait,” 1999.
- 638 [38] B. M. Nigg, G. K. Cole, and W. Nachbauer, “Effects of arch height of the foot on angular
639 motion of the lower extremities in running,” *J. Biomech.*, vol. 26, no. 8, pp. 909–916,
640 1993.

- 664 between arterial stiffness and peripheral artery disease as measured by radial artery
665 tonometry,” *Elsevier*, Accessed: Dec. 29, 2020. [Online]. Available:
666 <https://www.sciencedirect.com/science/article/pii/S0741521417315902>.
- 667 [47] C. W. Kim *et al.*, “Disturbed flow promotes arterial stiffening through thrombospondin-
668 1,” *Circulation*, vol. 136, no. 13, pp. 1217–1232, Sep. 2017, doi:
669 10.1161/CIRCULATIONAHA.116.026361.
- 670 [48] M. Audonnet, I. Signolet, C. Colas-Ribas, ... M. A.-C., and undefined 2017, “Exercise
671 Transcutaneous Oximetry of the Buttocks—External Validation With Computed
672 Tomography Angiography—,” *jstage.jst.go.jp*, doi: 10.1253/circj.CJ-16-1316.
- 673 [49] P. Abraham *et al.*, “Transcutaneous oxygen pressure measurements on the buttocks during
674 exercise to detect proximal arterial ischemia: Comparison with arteriography,”
675 *Circulation*, vol. 107, no. 14, pp. 1896–1900, Apr. 2003, doi:
676 10.1161/01.CIR.0000060500.60646.E0.
- 677 [50] A. Edwards, ... A. B.-B. journal of, and undefined 1994, “Systemic responses in patients
678 with intermittent claudication after treadmill exercise,” *ingentaconnect.com*, Accessed:
679 Dec. 29, 2020. [Online]. Available:
680 <https://www.ingentaconnect.com/content/jws/bjs/1994/00000081/00000012/art00009>.
- 681 [51] P. Hickman *et al.*, “Exercise in patients with intermittent claudication results in the
682 generation of oxygen derived free radicals and endothelial damage,” in *Advances in*
683 *Experimental Medicine and Biology*, 1994, vol. 361, pp. 565–570, doi: 10.1007/978-1-
684 4615-1875-4_96.
- 685 [52] F. J. Neumann *et al.*, “Activation and decreased deformability of neutrophils after
686 intermittent claudication,” *Circulation*, vol. 82, no. 3, pp. 922–929, 1990, doi:

- 687 10.1161/01.CIR.82.3.922.
- 688 [53] R. C. Drew, C. A. Blaha, M. D. Herr, R. Cui, and L. I. Sinoway, “Muscle mechanoreflex
689 activation via passive calf stretch causes renal vasoconstriction in healthy humans,” *Am. J.*
690 *Physiol. - Regul. Integr. Comp. Physiol.*, vol. 312, no. 6, pp. R956–R964, Jun. 2017, doi:
691 10.1152/ajpregu.00322.2016.
- 692 [54] A. Ross, Z. Gao, J. Luck, ... C. B.-A. of vascular, and undefined 2017, “Coronary
693 exercise hyperemia is impaired in patients with peripheral arterial disease,” *Elsevier*,
694 Accessed: Dec. 29, 2020. [Online]. Available:
695 [https://www.sciencedirect.com/science/article/pii/S0890509616307063?casa_token=TNc6](https://www.sciencedirect.com/science/article/pii/S0890509616307063?casa_token=TNc6pBrG8REAAAAA:Dy6hsLpAizs_tpEzdX7zPsySpRJCdXdiXzfuquKLywHqjLElCcCGZb8YAm286zFdabe_JPPFzVs)
696 [pBrG8REAAAAA:Dy6hsLpAizs_tpEzdX7zPsySpRJCdXdiXzfuquKLywHqjLElCcCGZb](https://www.sciencedirect.com/science/article/pii/S0890509616307063?casa_token=TNc6pBrG8REAAAAA:Dy6hsLpAizs_tpEzdX7zPsySpRJCdXdiXzfuquKLywHqjLElCcCGZb8YAm286zFdabe_JPPFzVs)
697 [8YAm286zFdabe_JPPFzVs](https://www.sciencedirect.com/science/article/pii/S0890509616307063?casa_token=TNc6pBrG8REAAAAA:Dy6hsLpAizs_tpEzdX7zPsySpRJCdXdiXzfuquKLywHqjLElCcCGZb8YAm286zFdabe_JPPFzVs).
- 698 [55] M. D. Muller, R. C. Drew, J. Cui, C. A. Blaha, J. L. Mast, and L. I. Sinoway, “Effect of
699 oxidative stress on sympathetic and renal vascular responses to ischemic exercise,”
700 *Physiol. Rep.*, vol. 1, no. 3, Aug. 2013, doi: 10.1002/phy2.47.
- 701 [56] D. Kim, M. Kuroki, J. Cui, Z. Gao, ... J. L.-A. J. of, and undefined 2020, “Cardiovascular
702 Neurohormonal Regulation: Systemic and regional hemodynamic response to activation
703 of the exercise pressor reflex in patients with,” *ncbi.nlm.nih.gov*, Accessed: Aug. 28,
704 2021. [Online]. Available: <https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7191495/>.
- 705 [57] M. D. Muller *et al.*, “Oxidative stress contributes to the augmented exercise pressor reflex
706 in peripheral arterial disease patients,” *J. Physiol.*, vol. 590, no. 23, pp. 6237–6246, Dec.
707 2012, doi: 10.1113/JPHYSIOL.2012.241281.
- 708 [58] M. D. Muller, A. B. Reed, U. A. Leuenberger, and L. I. Sinoway, “Physiology in
709 medicine: Peripheral arterial disease,” *J. Appl. Physiol.*, vol. 115, no. 9, pp. 1219–1226,

- 710 Nov. 2013, doi: 10.1152/JAPPLPHYSIOL.00885.2013.
- 711 [59] A. D. Kuo, J. M. Donelan, and A. Ruina, “Energetic consequences of walking like an
712 inverted pendulum: step-to-step transitions,” *Exerc. Sport Sci. Rev.*, vol. 33, no. 2, pp. 88–
713 97, 2005.
- 714 [60] M. B. Wiggin, G. S. Sawicki, and S. H. Collins, “An exoskeleton using controlled energy
715 storage and release to aid ankle propulsion,” in *Rehabilitation Robotics (ICORR), 2011
716 IEEE International Conference on*, 2011, pp. 1–5.
- 717 [61] J. J. Eng and D. A. Winter, “Kinetic analysis of the lower limbs during walking: What
718 information can be gained from a three-dimensional model?,” *J. Biomech.*, vol. 28, no. 6,
719 pp. 753–758, 1995, doi: 10.1016/0021-9290(94)00124-M.
- 720 [62] S. J. Chen *et al.*, “Bilateral claudication results in alterations in the gait biomechanics at
721 the hip and ankle joints,” *J. Biomech.*, vol. 41, no. 11, pp. 2506–2514, Aug. 2008, doi:
722 10.1016/j.jbiomech.2008.05.011.
- 723 [63] T. A. Bauer, E. P. Brass, and W. R. Hiatt, “Impaired muscle oxygen use at onset of
724 exercise in peripheral arterial disease,” *J. Vasc. Surg.*, 2004, doi:
725 10.1016/j.jvs.2004.06.025.
- 726 [64] I. I. Pipinos *et al.*, “The myopathy of peripheral arterial occlusive disease: Part 1.
727 Functional and histomorphological changes and evidence for mitochondrial dysfunction,”
728 *Vascular and Endovascular Surgery*, vol. 41, no. 6, pp. 481–489, Dec. 2008, doi:
729 10.1177/1538574407311106.
- 730 [65] M. McDermott, K. Liu, L. Tian, ... J. G.-J. of the, and undefined 2012, “Calf muscle
731 characteristics, strength measures, and mortality in peripheral arterial disease: a
732 longitudinal study,” *onlinejacc.org*, Accessed: Dec. 30, 2020. [Online]. Available:

- 733 <https://www.onlinejacc.org/content/59/13/1159.abstract>.
- 734 [66] N. S. Evans *et al.*, “Associations of calf skeletal muscle characteristics and peripheral
735 nerve function with self-perceived physical functioning and walking ability in persons
736 with peripheral artery disease,” *Vasc. Med.*, vol. 16, no. 1, pp. 3–11, Feb. 2011, doi:
737 10.1177/1358863X10395656.
- 738 [67] A. W. Gardner, D. E. Parker, P. S. Montgomery, S. M. Blevins, A. M. Teague, and A. I.
739 Casanegra, “Monitored daily ambulatory activity, inflammation, and oxidative stress in
740 patients with claudication,” *Angiology*, vol. 65, no. 6, pp. 491–496, 2014, doi:
741 10.1177/0003319713489769.
- 742 [68] J. Anderson, F. Epstein, ... C. M.-J. of the, and undefined 2009, “Multifactorial
743 determinants of functional capacity in peripheral arterial disease: uncoupling of calf
744 muscle perfusion and metabolism,” *onlinejacc.org*, Accessed: Dec. 30, 2020. [Online].
745 Available: <https://www.onlinejacc.org/content/54/7/628.abstract>.
746

1 **Table I. Demographic and anthropometric characteristics**

Clinical characteristics	Controls (n = 35)	Aortoiliac (n = 25)	Femoropopliteal (n = 23)	Multi-level (n = 49)
Age (years)	65.23 ± 9.51	60.67 ± 6.52	63.57 ± 6.69	64.55 ± 6.11
Body mass (kg)	79.90 ± 13.80	90.50 ± 14.90	84.20 ± 19.66	87.14 ± 17.17
Height (m)	1.74 ± 0.08	1.77 ± 0.09	1.75 ± 0.08	1.75 ± 0.05
BMI	26.37 ± 3.71	29.03 ± 5.59	27.37 ± 5.08	28.33 ± 5.59
Sex	29M	25M	22M 1F	49M
ABI Most affected limb	> 0.90	0.63 ± 0.15 ^b	0.54 ± 0.21 ^b	0.41 ± 0.19
ABI Least affected limb	> 0.90	0.85 ± 0.17 ^b	0.77 ± 0.19 ^b	0.62 ± 0.21
6MWD (m)		315.5 ± 100.6	320.9 ± 78.4	284.88 ± 103.8

2 a = significantly different compared to aortoiliac group

3 b = significantly different compared to multi-level group

4 BMI = body mass index

5 ABI = ankle brachial index

6 6MWD = six-minute walk distance

medRxiv preprint doi: <https://doi.org/10.1101/2022.02.14.22270963>; this version posted February 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

7 **Table II. Walking Impairment Questionnaire (WIQ) subscale scores**

WIQ subscale scores	Controls (n = 35)	Aortoiliac (n = 25)	Femoropopliteal (n = 23)	Multi-level (n = 49)
WIQ: Pain	95.71 ± 8.54	44.79 ± 24.98 ^a	57.07 ± 17.61 ^a	48.72 ± 21.69 ^a
WIQ: Distance	92.20 ± 15.99	24.12 ± 29.84 ^a	28.29 ± 26.06 ^a	16.74 ± 17.97 ^a
WIQ: Speed	80.37 ± 18.98	36.59 ± 25.04 ^a	27.93 ± 22.21 ^a	27.91 ± 25.06 ^a
WIQ: Stair	92.14 ± 15.97	38.89 ± 25.35 ^a	40.22 ± 28.47 ^a	30.95 ± 24.17 ^a

8 **a = significantly different compared to controls**9 **b = significantly different compared to the femoropopliteal group**10 **c = significantly different compared to the multi-level group**

medRxiv preprint doi: <https://doi.org/10.1101/2022.02.14.22270963>; this version posted February 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a U.S. Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

11 **Table III. Medical Outcomes Study Short Form 36 Health Survey (SF-36) subscale scores**

SF-36 subscale scores	Controls (n = 35)	Aortoiliac (n = 25)	Femoropopliteal (n = 23)	Multi-level (n = 49)
Physical function	88.67 ± 13.89	38.33 ± 16.40 ^a	43.47 ± 16.82 ^a	38.27 ± 17.75 ^a
Limitations due to physical health	91.94 ± 26.13	28.13 ± 37.09 ^a	39.13 ± 33.56 ^a	23.98 ± 34.60 ^a
Limitation due to emotional health	89.57 ± 26.70	61.11 ± 41.32 ^a	52.17 ± 39.98 ^a	60.54 ± 41.76 ^a
Energy	86.50 ± 17.39	49.90 ± 21.72 ^a	53.48 ± 22.00 ^a	44.44 ± 21.38 ^a
Emotional Health	77.79 ± 11.55	69.83 ± 15.85 ^d	63.22 ± 23.45 ^a	53.67 ± 21.01 ^{a,b}
Pain	82.35 ± 13.72	52.71 ± 23.97 ^a	49.17 ± 17.04 ^{a,d}	65.64 ± 22.64 ^{a,c}
Social function	94.83 ± 13.16	66.15 ± 27.46 ^a	65.98 ± 26.43 ^a	67.86 ± 24.34 ^a
General health	77.35 ± 17.37	52.71 ± 18.71 ^a	56.96 ± 23.05 ^a	53.27 ± 15.96 ^a

12 a = significantly different compared to controls

13 b = significantly different compared to aortoiliac group

14 c = significantly different compared to femoropopliteal group

15 d = significantly different compared to multi-level group

16

medRxiv preprint doi: <https://doi.org/10.1101/2022.02.14.22270963>; this version posted February 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

17 **Table IV. Quantitative gait biomechanics during pain free walking**

Gait Parameter	Controls (n = 35)	Aortoiliac (n = 25)	Femoropopliteal (n = 23)	Multi-level (n = 49)	All PAD (n = 97)
ADT	-0.32 ± 0.10	-0.24 ± 0.08 ^a	-0.26 ± 0.11	-0.25 ± 0.10 ^a	-0.25 ± 0.10 ^a
APT	1.38 ± 0.19	1.33 ± 0.18	1.31 ± 0.13	1.26 ± 0.22 ^a	1.29 ± 0.19 ^a
KET	0.69 ± 0.21	0.52 ± 0.30	0.52 ± 0.23	0.50 ± 0.24 ^a	0.51 ± 0.25 ^a
KFT	-0.14 ± 0.15	-0.21 ± 0.22	-0.17 ± 0.16	-0.21 ± 0.20	-0.20 ± 0.20
HET	0.85 ± 0.29	0.69 ± 0.21 ^a	0.59 ± 0.23 ^a	0.64 ± 0.21 ^a	0.64 ± 0.22 ^a
HFT	-1.05 ± 0.21	-0.88 ± 0.24 ^a	-0.81 ± 0.20 ^a	-0.81 ± 0.23 ^a	-0.82 ± 0.23 ^a
A1	-0.87 ± 0.29	-0.46 ± 0.17 ^a	-0.53 ± 0.19	-0.42 ± 0.25 ^a	-0.46 ± 0.22 ^a
K1	-0.91 ± 0.39	-0.71 ± 0.54	-0.62 ± 0.40	-0.61 ± 0.40 ^a	-0.64 ± 0.44 ^a
H1	0.41 ± 0.29	0.36 ± 0.29	0.36 ± 0.25	0.38 ± 0.29	0.37 ± 0.28
A2	-0.83 ± 0.25	-0.79 ± 0.27	-0.78 ± 0.30	-0.81 ± 0.25	-0.80 ± 0.26
K2	0.45 ± 0.22	0.29 ± 0.23 ^a	0.29 ± 0.14 ^a	0.31 ± 0.18 ^a	0.30 ± 0.19 ^a
H2	-0.84 ± 0.26	-0.66 ± 0.32	-0.62 ± 0.20 ^a	-0.61 ± 0.28 ^a	-0.62 ± 0.27 ^a
A3	2.70 ± 0.69	2.23 ± 0.64 ^a	1.90 ± 0.45 ^a	1.92 ± 0.64 ^a	2.00 ± 0.61 ^a
K3	-1.19 ± 0.47	-0.82 ± 0.23 ^a	-0.79 ± 0.28 ^a	-0.78 ± 0.37 ^a	-0.79 ± 0.32 ^a
H3	0.99 ± 0.23	0.76 ± 0.15 ^a	0.69 ± 0.23 ^a	0.72 ± 0.23 ^a	0.72 ± 0.21 ^a
AROM	18.78 ± 3.66	19.12 ± 4.17	19.29 ± 3.34	20.05 ± 3.44	19.63 ± 3.60
KROM	12.21 ± 3.67	11.49 ± 4.53	11.13 ± 4.80	11.17 ± 5.01	11.25 ± 4.80
HROM	40.10 ± 3.27	36.63 ± 5.37 ^a	36.33 ± 4.73 ^a	36.51 ± 5.22 ^a	36.50 ± 5.10 ^a

18 a = significantly different compared to controls

19

20 PAD = peripheral artery disease ADT = ankle dorsiflexor torque, APT = ankle plantarflexor
 21 torque, KET = knee extensor torque, KFT = knee flexor torque, HET = hip extensor torque, HFT
 22 = hip flexor torque, A1 = ankle power absorption during weight acceptance, A2 = ankle power
 23 absorption during single leg support, A3 = ankle power generation during push off, K1 = knee
 24 power absorption during weight acceptance, K2 = knee power generation during single leg support,
 25 K3 = knee power absorption during push off, H1 = hip power generation during weight acceptance,
 26 H2 = Hip power absorption during single leg support, H3 = hip power generation during push off,
 27 AROM = ankle range of motion, KROM = knee range of motion, HROM = hip range of motion

28

29 **Table V. Spatiotemporal gait measurements during pain free walking**

Gait Parameter	Controls (n = 32)	Aortoiliac (n = 25)	Femoropopliteal (n = 21)	Multi-level (n = 49)	All PAD (n = 95)
Step Length (m)	0.73 ± 0.06	0.68 ± 0.08	0.66 ± 0.07 ^a	0.65 ± 0.09 ^a	0.66 ± 0.08 ^a
Stride Length (m)	1.45 ± 0.11	1.36 ± 0.16	1.33 ± 0.14 ^a	1.29 ± 0.18 ^a	1.32 ± 0.17 ^a
Velocity (m/s)	1.31 ± 0.14	1.16 ± 0.15 ^a	1.11 ± 0.16 ^a	1.10 ± 0.19 ^a	1.12 ± 0.17 ^a
Stance Time (s)	0.60 ± 0.07	0.67 ± 0.07 ^a	0.68 ± 0.08 ^a	0.68 ± 0.09 ^a	0.68 ± 0.08 ^a
Stride Time (s)	1.12 ± 0.08	1.18 ± 0.09	1.21 ± 0.09 ^a	1.19 ± 0.09 ^a	1.19 ± 0.09 ^a
Swing Time (s)	0.52 ± 0.04	0.51 ± 0.04	0.53 ± 0.03	0.50 ± 0.04	0.51 ± 0.04
Step width (m)	0.07 ± 0.03	0.09 ± 0.04	0.10 ± 0.04 ^a	0.10 ± 0.04 ^a	0.10 ± 0.04 ^a
Cadence (steps/min)	107.94 ± 8.71	102.00 ± 7.92 ^a	99.92 ± 7.32 ^a	101.52 ± 7.37 ^a	101.30 ± 7.47 ^a

30 a = significantly different compared to controls

31 PAD = peripheral artery disease

medRxiv preprint doi: <https://doi.org/10.1101/2022.02.14.22270963>; this version posted February 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.

32 **Table VI.** Quantitative gait biomechanics during claudication pain induced walking

Gait Parameter	Controls (n = 35)	Aortoiliac (n = 25)	Femoropopliteal (n = 23)	Multi-level (n = 49)	All PAD (n = 97)
ADT	-0.32 ± 0.10	-0.22 ± 0.07 ^a	-0.28 ± 0.11	-0.22 ± 0.08 ^a	-0.24 ± 0.09 ^a
APT	1.38 ± 0.19	1.29 ± 0.20	1.23 ± 0.14	1.16 ± 0.25 ^a	1.21 ± 0.22 ^a
KET	0.69 ± 0.21	0.56 ± 0.30	0.56 ± 0.25	0.50 ± 0.21 ^a	0.53 ± 0.24 ^a
KFT	-0.14 ± 0.15	-0.20 ± 0.23	-0.17 ± 0.20	-0.17 ± 0.19	-0.18 ± 0.20
HET	0.85 ± 0.29	0.69 ± 0.20	0.58 ± 0.24 ^a	0.62 ± 0.22 ^a	0.63 ± 0.22 ^a
HFT	-1.05 ± 0.21	-0.88 ± 0.25	-0.75 ± 0.25 ^a	-0.73 ± 0.24 ^a	-0.77 ± 0.25 ^a
A1	-0.67 ± 0.29	-0.46 ± 0.18 ^a	-0.58 ± 0.30 ^d	-0.36 ± 0.19 ^{a,c}	-0.44 ± 0.23 ^a
K1	-0.91 ± 0.39	-0.76 ± 0.54	-0.70 ± 0.46	-0.58 ± 0.36 ^a	-0.65 ± 0.44 ^a
H1	0.41 ± 0.29	0.38 ± 0.30	0.32 ± 0.25	0.34 ± 0.22	0.35 ± 0.25
A2	-0.83 ± 0.25	-0.81 ± 0.39	-0.86 ± 0.38	-0.86 ± 0.28	-0.84 ± 0.33
K2	0.45 ± 0.22	0.32 ± 0.23	0.33 ± 0.21	0.29 ± 0.18 ^a	0.31 ± 0.20 ^a
H2	-0.84 ± 0.26	-0.72 ± 0.34	-0.61 ± 0.27 ^a	-0.63 ± 0.27 ^a	-0.65 ± 0.29 ^a
A3	2.70 ± 0.69	2.07 ± 0.68 ^{a,d}	1.71 ± 0.55 ^a	1.60 ± 0.60 ^{a,b}	1.75 ± 0.64 ^a
K3	-1.19 ± 0.47	-0.83 ± 0.30 ^a	-0.71 ± 0.31 ^a	-0.69 ± 0.33 ^a	-0.73 ± 0.32 ^a
H3	0.99 ± 0.23	0.78 ± 0.24 ^a	0.62 ± 0.27 ^a	0.63 ± 0.23 ^a	0.66 ± 0.25 ^a
AROM	18.78 ± 3.66	20.66 ± 4.82	21.45 ± 3.56	22.06 ± 3.49 ^a	21.56 ± 3.89 ^a
KROM	12.21 ± 3.67	12.94 ± 4.54	11.53 ± 5.63	10.78 ± 5.19	11.51 ± 5.17
HROM	40.10 ± 3.27	36.70 ± 5.37	36.11 ± 5.96 ^a	35.14 ± 5.23 ^a	35.77 ± 5.43 ^a

33 a = significantly different compared to controls

34 b = significantly different compared to aortoiliac

35 c = significantly different compared to femoropopliteal

36 d = significantly different compared to multi-level

37 PAD = peripheral artery disease ADT = ankle dorsiflexor torque, APT = ankle plantarflexor
 38 torque, KET = knee extensor torque, KFT = knee flexor torque, HET = hip extensor torque, HFT
 39 = hip flexor torque, A1 = ankle power absorption during weight acceptance, A2 = ankle power
 40 absorption during single leg support, A3 = ankle power generation during push, K1 = knee power
 41 absorption during weight acceptance, K2 = knee power generation during single leg support, K3
 42 = knee power absorption during push off, H1 = hip power generation during weight acceptance,
 43 H2 = Hip power absorption during single leg support, H3 = hip power generation during push off

44 **Table VII. Spatiotemporal gait measurements during claudication pain induced walking**

Gait Parameter	Control (n = 32)	Aortoiliac (n = 25)	Femoropopliteal (n = 21)	Multi-level (n = 49)	All PAD (n = 95)
Step Length (m)	0.73 ± 0.06	0.65 ± 0.09 ^a	0.65 ± 0.08 ^a	0.62 ± 0.09 ^a	0.63 ± 0.09 ^a
Stride Length (m)	1.45 ± 0.11	1.30 ± 0.18 ^a	1.30 ± 0.17 ^a	1.22 ± 0.19 ^a	1.26 ± 0.18 ^a
Velocity (m/s)	1.31 ± 0.14	1.11 ± 0.19 ^a	1.08 ± 0.21 ^a	1.04 ± 0.20 ^a	1.07 ± 0.20 ^a
Stance Time (s)	0.60 ± 0.07	0.68 ± 0.08 ^a	0.71 ± 0.08 ^a	0.69 ± 0.10 ^a	0.69 ± 0.09 ^a
Stride Time (s)	1.12 ± 0.09	1.18 ± 0.10	1.22 ± 0.11 ^a	1.18 ± 0.13	1.19 ± 0.12 ^a
Swing Time (s)	0.52 ± 0.04	0.50 ± 0.04	0.52 ± 0.05	0.50 ± 0.04	0.51 ± 0.04
Step width (m)	0.07 ± 0.03	0.09 ± 0.04	0.10 ± 0.03 ^a	0.10 ± 0.04 ^a	0.10 ± 0.04 ^a
Cadence (steps/min)	107.94 ± 8.71	102.00 ± 8.64	99.07 ± 8.76	103.14 ± 15.47	101.94 ± 12.66 ^a

45 a = significantly different compared to controls

46 PAD = peripheral artery disease

medRxiv preprint doi: <https://doi.org/10.1101/2022.02.14.22270963>; this version posted February 15, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.